Atopic Dermatitis

“It is critical that our clinical data represent the diversity in the world around us, and these results further reinforce our commitment to providing meaningful innovation for immune-mediated skin diseases," said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.

Kilian Eyerich, MD, PhD, shares insights into an EADV 2024 presentation on upadacitinib’s ability to achieve almost total skin clearance in the head and neck regions with minimal effect on quality of life.

The study found that over 80% of patients who responded to lebrikizumab at week 16 maintained clear or almost-clear skin after 3 years.

A new analysis from phase 3 studies shows Rinvoq's effectiveness for moderate to severe AD with head and neck involvement.

Catch up on eczema advancements throughout the year, including news on contact dermatitis, chronic hand eczema, and more.

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space.

Dermavant’s sNDA for tapinarof cream 1% for AD is still under review with the FDA.

Researchers analyzed APPs treatment and perceptions on AD in studies focusing on patient satisfaction and patients with skin of color.

The IL-13 inhibitor, recently FDA-approved for moderate to severe AD, reached all primary endpoints in the study focusing on patients with skin of color.

Ebglyss is now approved for children and adults aged 12 years and older.

Hurricane flooding results in a surge of mold, mildew, and allergens, which can trigger or exacerbate AD symptoms.

The TARGET-DERM registry longitudinal study highlighted the continued trend of the failure to escalate atopic dermatitis treatments when patients do not meet their therapeutic targets.

This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.

A recent study revealed a spectrum of photosensitivity in AD, with varying symptoms and sensitivities.

By setting higher treatment goals, the AHEAD recommendations emphasize the importance of achieving optimal targets for both skin clearance and itch relief in atopic dermatitis.

Results from the study highlight that the therapy improves AD symptoms over time, with 71.9% of participants achieving substantial improvement.

The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.

The study found that after 4 weeks of using the action plan, AD severity decreased markedly, with many patients achieving mild AD status.

The study found 95.8% of ocular AEs occurred in AD patients, while SA patients reported only 4.2% of these events.

Patients with AD and psoriasis both report diminished levels of happiness compared to the general population.

Researchers stated the integration of wearable sensors with AI could potentially revolutionize care for patients with atopic dermatitis.

Learn more about the OX40-OX40L pathway and 2 drugs heading toward phase 3 trials.

Researchers suggested that itch control is key in reducing disease burden and improving life quality for patients with psoriasis and atopic dermatitis.

John Browning, MD, FAAD, FAAP, MBA, discusses the new online platform that allows young patients to share their skin journey with others.

Kindred spoke with Dermatology Times to discuss AbbVie's recent Science of Skin event and improving access to equitable dermatological care.

Jared Gollob, MD, shares highlights of Kymera Therapeutics' recent JID publication.

Kristine Kucera, MPAS, PA-C, DHS, discusses her patient's challenging atopic dermatitis that was eventually cleared with upadacitinib.

Researchers said they hope this consensus guides prescribing decisions among clinicians and encourages development of a standard approach.

The 15-piece questionnaire is designed to be quick and easy to use during consultations, with particular benefits across numerous specialties.